Company* (Symbol)

Product

Description

Indication

Status (Date)**

CANCER

AltaRex Corp. (Canada; TSE:AXO)

OvaRex MAb

Anti-idiotype induction therapy-based vaccine; consists of modified murine monoclonal antibody that binds to CA125 cancer antigen

Ovarian cancer

Presented data from 25-patient open-label clinical study at the 31st Annual Meeting of the Society of Gynecologic Oncologists in San Diego

BioMedicines Inc.*

Biomed 101

Orally bioavailable drug that binds to the leukotriene B4 receptor and inhibits cell damage

Kidney cancer

Initiated Phase Ib trial of Biomed 101 in combination with interleukin-2 (2/15)

Cell Genesys Inc. (CEGE) and Japan Tobacco Inc. (Japan)

GVAX lung cancer vaccine

Cancer vaccine comprised of tumor cells which have been irradiated and genetically modified to secrete granulocyte-macrophage-colony stimulating factor (GM-CSF)

Non-small-cell lung cancer

Reported results from initial pilot study; initiated Phase I/II trial (2/28)

Cell Pathways Inc. (CLPA)

Aptosyn

Exisulind; orally active drug designed to induce apoptosis in precancerous cells; inhibits a cyclic GMP phosphodiesterase

Breast and colorectal cancers

Initiated Phase I trials of Aptosyn in combination with Xeloda (capecitabine; marketed by Roche Laboratories Inc.; Switzerland) (2/2)

Corixa Corp. (CRXA) and Schering-Plough Corp. (NYSE:SGP)

Melacine

Therapeutic cancer vaccine made of lysed cells from 2 melanoma cell lines with a broad array of melanoma antigens, combined with Detox adjuvant (contains monophosphoryl lipid A and mycobacterial cell-wall skeleton)

Stage II melanoma

Presented data from Phase III trial at Melanoma at the Millennium meeting in Phoenix (2/18)

Immunomedics Inc. (IMMU)

LymphoCide

Humanized anti-CD22 antibody consisting of murine binding sites linked to immunoglobulin backbone; labeled with iodine-131

Non-Hodgkin's lymphoma

Phase I data published in 1/00 issue of Leukemia and Lymphoma (2/11)

Magainin Pharmaceuticals Inc. (MAGN)

Squalamine

Synthetically produced version of a compound found in the dogfish shark; anti-angiogenic compound combines a steroid and a polyamine

Various advanced cancers; expected to include head and neck, esophageal, breast and uterine cancers

Initiated trial to evaluate safety of squalamine in combination with cisplatin (2/17)

Squalamine

Synthetically produced version of a compound found in the dogfish shark; anti-angiogenic compound combines a steroid and a polyamine

Advanced ovarian cancer

Initiated two Phase II trials of squalamine, one in combination with carboplatin and one in combination with carboplatin and paclitaxel (2/3)

NeoRx Corp. (NERX)

Skeletal Targeted Radiotherapy

Small-molecule carrier of the radionuclide holmium-166, designed to deliver radiation therapy selectively to the disease site

Multiple myeloma

Presented Phase II safety data at Cruttendon Roth conference in Laguna Niguel, Calif. (2/23)

Northwest Biotherapetuics Inc.*

Dendritic cell-based immunotherapy composed of a patient's own purified dendritic cells, which have been removed from the patient and treated with recombinant prostate-specific membrane antigen

Hormone refractory metastatic prostate cancer

Initiated clinical trial (2/14)

Procept Inc. (biotech subsidiary of HeavenlyDoor.com; HVDC)

BG

0-6-Benzylguanine chemosensitizing agent; acts by inactivating tumor AGT, a DNA repair protein that interferes with the effectiveness of 06-alkylating chemotherpeutic agents

Cerebral anaplastic gliomas

National Cancer Institute initiated 2nd Phase II trial of product in combination with carmustine (2/11)

Telik Inc.*

TER286

Small-molecule cytotoxic agent

Advanced solid tumors and non-Hodgkin's lymphoma

Initiated Phase I trial (2/1)

CARDIOVASCULAR

Alliance Pharmaceutical Corp. (ALLP)

Oxygent

Perflubon-based emulsion; intravascular oxygen carrier

Cardiac surgery with cardiopulmonary bypass support; reduction of need for donor blood transfusions

Presented preliminary efficacy results from three Phase II studies at the Cambridge Healthcare Institute's Sixth Annual Blood Product Safety Conference in Washington (2/15)

AVI BioPharma Inc. (AVII)

Resten-NG

Synthetic polymer antisense compound targeting c-myc oncogene, which has been implicated in cell proliferation

Restenosis

Lenox Hill Hospital in New York selected as primary site for Phase II trials (2/2)

BioPure Corp. (BPUR)

Hemopure (HBOC-201)

Hemoglobin glutamer-250 (bovine); each unit of product contains approximately 30 grams of purified, chemically

Alternative to red blood cell transfusion in patients undergoing vascular surgery

Phase II trial results published in (2/10) 2/00 Journal of Vascular Surgery

DRAXIS Health Inc. (Canada; TSE:DAX)

Fibrimage

Recombinant polypeptide with high-binding affinity for fibrin, the primary component of deep vein thrombosis; labeled with technetium-99

Detection of deep vein thrombosis

Initiated Phase III trial (2/2)

COR Therapeutics Inc. (CORR) and Schering-Plough Corp. (NYSE:SGP)

Integrilin (FDA-approved)

Eptifibatide; small-molecule compound (derived from rattlesnake venom) that inhibits GPIIb/IIIa receptor that mediates platelet aggregation

Patients undergoing coronary intervention with stenting

Halted enrollment in 2400-patient ESPRIT study after Data Safety Monitoring Committee's interim analysis found an almost 50% reduction in death or heart attack at 30 days (2/4)

CV Therapeutics (CVTX) and Biogen Inc. (BGEN)

CVT-124

Selective adenosine A(1) antagonist (intravenous)

Moderate to severe congestive heart failure

Completed Phase II trial (2/17)

Pharmacyclics Inc. (PCYC)

Antrin Injection

Motexafin lutetium; water-soluble photosensitizing agent that accumulates selectively in vascular plaque; targeted areas are exposed to far-red light delivered by an optical fiber inserted into the vessel using standard techniques

Patients undergoing balloon angioplasty (prevention of restenosis)

Initiated Phase I trial (2/29)

United Therapeutics Corp. (UTHR)

Beraprost tablets; oral form of prostacyclin, which is produced in blood vessels to keep them dilated and free of platelet aggregation

Moderate pulmonary hypertension

Initiated Phase III trial (2/24)

CENTRAL NERVOUS SYSTEM

Acorda Therapeutics Inc.* and Elan Corp. plc (Ireland; NYSE: ELN)

Fampridine-SR

4-aminopyridine; sustained-release oral tablet formulation

Chronic spinal cord injury

Announced plan to start Phase II trial (2/14)

Angiotech Pharmaceuticals Inc. (Canada; ANPI)

Micellular paclitaxel; generic version of active ingredient in anticancer drug Taxol

Secondary progressive multiple sclerosis

Reported preliminary results from Phase I/II trial (2/25)

AXONYX Inc. (OTC BB: AXYX)

Phenserine

Brain-targeted, reversible inhibitor of acetylcholinesterase enzyme

Alzheimer's disease

Continued Phase I trial by administering drug to 2nd group of healthy, elderly volunteers (2/2)

Biogen Inc. (BGEN)

Avonex (FDA-approved)

Interferon beta-1a

Delay of clinically definite multiple sclerosis

CHAMPS study halted after Data Monitoring Committee found abeneficial effect on the primary endpoint had been established at interim analysis, exceeding the pre-established criteria required for early termination (2/1)

Cephalon Inc. (CEPH)

Provigil (FDA-approved)

Modafinil; oral formulation of synthetic compound that is thought to affect alpha-adrenergic receptors in the brain

Excessive daytime sleepiness associated with obstructive sleep apnea

Reported positive results in double-blind, placebo-controlled study; initiated additional trial with the intention of pursuing a label extension (2/3)

Neurobiological Technologies Inc. (OTC BB: NTII) and Merz + Co. GmbH & Co. (Germany)

Memantine

Orally available neuroprotective agent that appears to restore damaged nerve cells and block excitatory signals by modulating the N-methyl-D-aspartate (NMDA) receptor on cell membranes

Advanced Alzheimer's disease

Reported positive results from Phase III trial (2/22)

DIABETES

DepoMed Inc. (AMEX:DMI)

Metformin GR

Extended-release dosage formulation of metformin

Diabetes

Presented results of Phase I trial comparing Metformin GR to Glucophage (marketed by Bristol-Myers Squibb Co. [NYSE:BMY]) at the Cruttendon Roth Emerging Growth Conference in Laguna Niguel, Calif. (2/22)

Generex Biotechnology Corp. (Canada; OTC BB:GNBT)

Oralgen (Oralin outside the U.S.)

Oral insulin; administered as a fine spray into the oral cavity using a lightweight handheld aerosol applicator

Diabetes

Completed clinical trials under a number of study protocols at the Diabetes and Glandular Disease Clinic in San Antonio (2/17)

Oralgen (Oralin outside the U.S.)

Oral insulin; administered as a fine spray into the oral cavity using a lightweight handheld aerosol applicator

Type II diabetes

Completed a series of short-term trials using Oralgen in combination with metformin hydrochloride at the National Research Institute (2/23)

INFECTION

Abbott Laboratories (NYSE: ABT)

ABT-378

Ritonavir; HIV protease inhibitor

HIV infection

Presented data from ongoing Phase II combination therapy study at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (2/1)

Agouron Pharmaceuticals Inc. (unit of Warner-Lambert Co.; NYSE:WLA)

Viracept (FDA-approved)

Nelfinavir mesylate; HIV protease inhibitor

HIV infection in pregnant women

Announced results from Pediatric AIDS Clinical Trials Group (PACTG) study 353 of Viracept as part of combination therapy; data presented at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (2/2)

Viracept (FDA-approved)

Nelfinavir mesylate; HIV protease inhibitor

HIV infection that fails exclusive treatment with nucleoside reverse transcriptase inhibitors

Reported results from Adult AIDS Clinical Trial Group (AACTG) 364 combination therapy study; data presented at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (2/2)

Aronex Pharmaceuticals Inc. (ARNX)

Nyotran

Liposomal formulation of anti-fungal agent Nystatin

Cryptococcal meningitis

Announced preliminary Phase III results, in which Nyotran failed to demonstrate equivalence with amphotericin B (2/16)

AVANT Immunotherapeutics (AVAN)

CETi-1

Therapeutic vaccine against endogenous cholesteryl ester transfer protein (CETP), a key intermediary in the distribution of cholesterol between high-density lipoprotein and low-density lipoprotein

Atherosclerosis; low HDL

Completed enrollment in Phase I trial (2/3)

BioCryst Pharmaceuticals Inc. (BCRX) and the R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson; NYSE:JNJ)

RWJ-270201 (BCX-1812)

Oral small-molecule

Influenza infection inhibitor of neuraminidase enzyme, which promotes spread of the influenza virus by breaking the chemical strands that hold new viruses to cell surfaces

Initiated Phase III trials in North America and Europe (2/8)

Boehringer Ingelheim GmbH International (Germany)

Viramune (FDA-approved)

Nevirapine; nonnucleoside reverse transcriptase inhibitor

Advanced HIV infection

Reported data from combination study with Retrovir (zidovudine; AZT) and Epivir (lamivudine; 3TC), both of which are marketed by Glaxo Wellcome plc (NYSE:GLX); data presented at 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (2/3)

Boston Biomedica Inc. (BBII)/TD>

Use of pressure cycling technology to inactivate pathogens in human plasma

Elimination of pathogens from plasma supply

Presented data at the Cambridge Healthtech Institute's Sixth Annual Blood Safety and Screening Conference in McLean, Va. (2/14)

Enzo Biochem Inc. (NYSE: ENZ)

Gene therapy using HGTV43 vector to transduce stem cells ex vivo with antisense RNA to HIV-1

HIV infection

Reported Phase I trial data at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (2/1)

Glaxo Wellcome plc (NYSE:GLX)

Ziagen

Abacavir; nucleoside analogue reverse transcriptase inhibitor (oral; tablet and liquid; twice-daily dosing)

HIV infection

Presented data from study comparing triple nucleoside regimen of Ziagen (abacavir sulfate) and Combivir (lamivudine/zidovudine; also marketed by Glaxo) to a regimen of Crixivan (indinavir sulfate; marketed by Merck & Co. Inc. [NYSE:MRK]) (2/2)

ID Biomedical Corp. (Canada; IDBE)

StreptAvax

Group A streptococcus vaccine

Prevention of group A streptococcus infection

Reported results from early human study (2/9)

The Immune Response Corp. (IMNR)

Remune

Envelope-depleted, inactivated AIDS virus (emulsified with adjuvant)

HIV infection

Presented Phase II trial results at the World Health Organization and the Joint United Nations Programme on HIV/AIDS vaccine advisory committee meeting in Geneva (2/23)

InterMune Pharmaceuticals*

Actimmune (FDA-approved)

Interferon gamma-1b

Cryptococcal meningitis

Initiated Phase II trial (2/2)

Micrologix Biotech Inc.* (Canada)

MBI 853NL

Intranasally delivered antibiotic

Prevention and treatment of Staphylococcus aureus infection, including methicillin-resistant S. aureus

Initiated Phase I trial (2/15)

Progenics Pharmaceuticals Inc. (PGNX)

PRO 542

Fusion protein that incorporates HIV binding region of human cell surface receptor (CD4) into a human antibody molecule; binds to GP120

HIV infection in children

Presented Phase I/II data at the 7th Conference on Retroviruses and Opportunistic Infections (2/2)

Ribozyme Pharmaceuticals Inc. (RZYM) and Eli Lilly and Co. (NYSE:LLY)

LY466700

Chemically synthesized ribozyme dessigned to selectively cut hepatitis C virus RNA in a conserved region and inhibit viral replication

HCV infection

Initiated Phase I trial (2/16)

Sarawak MediChem Pharmaceuticals*

(+) - Calanolide A; plant-based, naturally occurring non-nucleoside reverse transcriptase inhibitor; orally available

HIV infection (treatment naive patients)

Presented data from two Phase Ib monotherapy studies conducted in the U.S., Malaysia and Singapore at the 7th Conference on Retroviruses and Opportunistic Infections in San Francisco (2/1)

Triangle Pharmaceuticals Inc. (VIRS)

DAPD

Dioxolane purine nucleoside reverse transcriptase inhibitor that is rapidly converted in humans into its active metabolite, DXG

HIV infection

Reported initial results of Phase I/II monotherapy trial (2/2)

Triangle Pharmaceuticals Inc. (VIRS)

Coviracil

Emtricitabine; antiviral nucleoside analogue

HIV infection

Reported data on Coviracil in combination with didanosine and efavirenz (2/1)

MISCELLANEOUS

Cambridge Antibody Technology (UK; LSE:CAT) and BASF Pharma (Germany)

D2E7

Fully human antibody against tumor necrosis factor alpha

Rheumatoid arthritis

Initiated Phase III trials (2/4)

Cellegy Pharmaceuticals Inc. (CLGY)

Anogesic

Proprietary formulation of nitroglycerin ointment

Hemorrhoids

Phase II trial to be initiated (2/2)

Connetics Corp. (CNCT)

Luxiq (FDA-approved)

Betamethasone valerate foam 0.12%; stabilized foam formulation of mid-potency steroid

Non-scalp psoriasis

Study presented at Skin Disease Education Foundation's 24th annual seminar in Hawaii (2/15)

Cypress Bioscience Inc. (CYPB) and Fresenius Hemotechnology Inc. (subsidiary of Fresenius AG; Germany)

Prosorba Column (FDA-approved)

Disposable filter that uses Protein A to remove circulating immune complexes from patient's blood

Severe rheumatoid arthritis that is resistant to other therapies

Reported results from a survey of clinical usage (2/24)

Genelabs Technologies Inc. (GNLB)

GL701

Dehydropieandosterone (DHEA); naturally occurring hormone produced by the adrenal glands

Systemic lupus erythematosus

Reported statistically significant positive results from Phase III trial at the 8th International Scientific Conference on Lymphocyte Activation and Immune Regulation in Newport Beach, Calif. (2/14)

Genelabs Technologies Inc. (GNLB)

GL701

Dehydropieandosterone (DHEA); naturally occurring hormone produced by the adrenal glands

Systemic lupus erythematosus

Discussion of DHEA, including Phase III results of GL701, presented at the American College of Rheumatology conference "Clinical Update on New Therapies in Rheumatic Diseases" (2/25)

IDEC Pharmaceuticals (IDPH)

IDEC-152

Primatized anti-CD23 monoclonal antibody

Allergic asthma

Initiated Phase I trial (2/3)

La Jolla Pharmaceutical Co. (LJPC)

LJP 394

Molecule (toleragen) that binds to surface of B cells and shuts off production of antibodies to double-stranded DNA

Lupus

Announced new Phase II/III results at the Biotechnology Industry Organization's CEO & Investor Conference in New York; drug showed significant improvement in time to renal flares among high-affinity patients (2/16)

Millennium Pharmaceuticals Inc. (MLNM)

LDP-02

Humanized monoclonal antibody against alpha-4 beta-7, an integrin on inflammatory cells which causes the cells to adhere to the gastrointestinal tract

Crohn's disease

Initiated Phase II trial (2/24)

NPS Pharmaceuticals Inc. (NPSP)

ALX1-11

Injectable version of human parathyroid hormone

Osteoporosis

Initiated Phase III trial (2/15)

Protein Design Labs Inc. (PDLI)

SMART (humanized) antibody against gamma interferon

Autoimmune diseases

Initiated Phase I trial in normal volunteers (2/24)

PPL Therapeutics plc (LSE:PTH)

Transgenically produced alpha one antitrypsin (AAT)

AAT congenital deficiency

Announced additional results from two Phase II trials (2/9)

SciClone Pharmaceuticals

CPX

8-cylcopentyl-1, 3-dipropylxanthine; orally administered protein repair therapy; intended to repair protein associated defect in CFTR (cystic fibrosis transmembrane regulator) protein responsible for 70% of cystic fibrosis cases

Cystic fibrosis

In Phase II trial, drug absorption characteristics of CF patients precluded measurements of sustained blood concentrations of CPX necessary to evaluate efficacy; new oral formulation program is intended to address the issue (2/15)

Unigene Laboratories Inc. (OTC BB: UGNE)

Nasal calcitonin formulation

Osteoporosis

Initiated U.S. clinical studies (2/7)

Unigene Laboratories Inc. (OTC BB: UGNE) and Warner-Lambert Co. (NYSE: WLA)

Nasal calcitonin formulation

Osteoporosis

Completed testing of clinical supplies of oral calcitonin for upcoming Phase I/II trial (2/25)

XTL Biopharmaceuticals Ltd. (Israel)

XTL-001

A combination of two high-affinity, fully human monoclonal antibodies that bind to distinct sites on the surface antigen of hepatitis B to neutralize the virus and limit viral escape

Hepatitis B infection

Presented initial data from Phase I trial at the Biotechnology Industry Organization's CEO and Investor Conference in New York (2/16)

Notes:

* Indicates a privately held company

** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SBI=Stockholm Borsinformation; SSE = Swedish Stock Exchange; TSE = Toronto Stock Exchange

ND = Not disclosed

No Comments